NCT04814615View on ClinicalTrials.gov

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

March 15, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

89Zr-daratumumab PET/CT

CD38-targeting imaging

Trial Locations (2)

33136

RECRUITING

University of Miami, Miami

92614

RECRUITING

Hoag Memorial Hospital Presbyterian, Irvine

All Listed Sponsors
lead

Hoag Memorial Hospital Presbyterian

OTHER